JP2010514828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514828A5 JP2010514828A5 JP2009544447A JP2009544447A JP2010514828A5 JP 2010514828 A5 JP2010514828 A5 JP 2010514828A5 JP 2009544447 A JP2009544447 A JP 2009544447A JP 2009544447 A JP2009544447 A JP 2009544447A JP 2010514828 A5 JP2010514828 A5 JP 2010514828A5
- Authority
- JP
- Japan
- Prior art keywords
- propyl
- oxadiazol
- piperidine
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 oxadiazol-5-yl Chemical group 0.000 claims 43
- 150000003839 salts Chemical class 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 23
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- DYWOLPXRUNVGOO-UHFFFAOYSA-N 3-tert-butyl-5-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-1,2,4-oxadiazole Chemical compound CC(C)(C)C1=NOC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 DYWOLPXRUNVGOO-UHFFFAOYSA-N 0.000 claims 1
- DPSQJTZWTDOKFO-UHFFFAOYSA-N 5-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 DPSQJTZWTDOKFO-UHFFFAOYSA-N 0.000 claims 1
- IATPCIBOIGPQOH-UHFFFAOYSA-N 5-[4-[3-(3-fluoro-4-methylsulfonylphenoxy)propyl]piperidin-1-yl]-3-propyl-1,2,4-oxadiazole Chemical compound CCCC1=NOC(N2CCC(CCCOC=3C=C(F)C(=CC=3)S(C)(=O)=O)CC2)=N1 IATPCIBOIGPQOH-UHFFFAOYSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 0 *C(CCOc1cc(*)c(*)cc1)C(CC1)CCN1C1NC(*)=**1 Chemical compound *C(CCOc1cc(*)c(*)cc1)C(CC1)CCN1C1NC(*)=**1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0700123A GB0700123D0 (en) | 2007-01-04 | 2007-01-04 | GPCR agonists |
| GB0719760A GB0719760D0 (en) | 2007-10-10 | 2007-10-10 | GPCR agonists |
| PCT/GB2008/050010 WO2008081204A1 (en) | 2007-01-04 | 2008-01-04 | Piperidine gpcr agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010514828A JP2010514828A (ja) | 2010-05-06 |
| JP2010514828A5 true JP2010514828A5 (Direct) | 2011-02-17 |
Family
ID=39203133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544447A Pending JP2010514828A (ja) | 2007-01-04 | 2008-01-04 | ピペリジンｇｐｃｒアゴニスト |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100048632A1 (Direct) |
| EP (2) | EP2114933B1 (Direct) |
| JP (1) | JP2010514828A (Direct) |
| AT (1) | ATE523507T1 (Direct) |
| BR (1) | BRPI0806498A2 (Direct) |
| CA (1) | CA2674348A1 (Direct) |
| CY (1) | CY1112483T1 (Direct) |
| DK (1) | DK2114933T3 (Direct) |
| EA (1) | EA015129B1 (Direct) |
| ES (1) | ES2373181T3 (Direct) |
| HR (1) | HRP20110852T1 (Direct) |
| PL (1) | PL2114933T3 (Direct) |
| PT (1) | PT2114933E (Direct) |
| RS (1) | RS52065B (Direct) |
| SI (1) | SI2114933T1 (Direct) |
| WO (1) | WO2008081204A1 (Direct) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008000017A1 (es) * | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| JP2010539152A (ja) | 2007-09-10 | 2010-12-16 | プロシディオン・リミテッド | 代謝障害の治療のための化合物 |
| GB0812648D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0812649D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| EP2445878A1 (en) | 2009-06-24 | 2012-05-02 | Boehringer Ingelheim International GmbH | New compounds, pharmaceutical composition and methods relating thereto |
| JP2012530758A (ja) | 2009-06-24 | 2012-12-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| ITMI20100770A1 (it) | 2010-05-03 | 2011-11-04 | Dipharma Francis Srl | Procedimento per la preparazione di 3-(4-piridinil)-propanolo e suoi intermedi |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| ITMI20100984A1 (it) | 2010-05-31 | 2011-12-01 | Dipharma Francis Srl | Procedimento per la preparazione di ossadiazoli |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| KR20130138768A (ko) | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 5-ｈｔ2ｃ 아고니스트의 신속-용해성 투여 형태 |
| JP6272695B2 (ja) | 2010-09-01 | 2018-01-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
| AU2011296033A1 (en) | 2010-09-01 | 2013-04-04 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-HT2C agonists |
| SG10201506870PA (en) | 2010-09-01 | 2015-10-29 | Arena Pharm Inc | Salts of lorcaserin with optically active acids |
| AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013187646A1 (en) | 2012-06-12 | 2013-12-19 | Chong Kun Dang Pharmaceutical Corp. | Piperidine derivatives for gpr119 agonist |
| CN110028494A (zh) | 2013-11-26 | 2019-07-19 | 株式会社钟根堂 | 酰胺衍生物、其立体异构体或其药学上可接受的盐及包含其的药物组合物 |
| KR101726819B1 (ko) | 2014-10-27 | 2017-04-13 | 동아에스티 주식회사 | Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| DE4222565A1 (de) * | 1992-07-09 | 1994-01-13 | Hoechst Ag | Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen |
| US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
| DE4311967A1 (de) * | 1993-04-10 | 1994-10-13 | Hoechst Ag | Smektische Flüssigkristallmischung |
| DE4311968A1 (de) * | 1993-04-10 | 1994-10-20 | Hoechst Ag | Smektische Flüssigkristallmischung |
| EP0664798B1 (en) | 1993-08-13 | 1999-12-29 | Zeneca Limited | Thiadiazole derivatives and their use as fungicides or insecticides |
| CA2229617A1 (en) * | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| ZA977103B (en) | 1996-08-09 | 1999-02-08 | Eisai Co Ltd | Benzopiperidine derivatives |
| GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
| CA2344591A1 (en) | 1998-09-01 | 2000-03-09 | Basf Aktiengesellschaft | Methods for improving the function of heterologous g protein-coupled receptors |
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| WO2003020217A2 (en) | 2001-08-31 | 2003-03-13 | University Of Connecticut | Novel pyrazole analogs acting on cannabinoid receptors |
| GB0109103D0 (en) | 2001-04-11 | 2001-05-30 | Pfizer Ltd | Novel compounds |
| FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
| FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
| KR100903760B1 (ko) | 2001-09-21 | 2009-06-19 | 솔베이 파마슈티칼스 비. 브이 | Ｃｂ1-길항 작용을 가지는 신규한4,5-디하이드로-1ｈ-피라졸 유도체 |
| BR0208253A (pt) | 2001-09-21 | 2004-04-13 | Solvay Pharm Bv | Compostos, composições farmacêuticas, método de preparação de composições farmacêuticas, processo para preparação de compostos, e, uso de um composto |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| FR2831883B1 (fr) | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
| SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| FR2833842B1 (fr) | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
| WO2003063781A2 (en) | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| WO2003075660A1 (en) | 2002-03-06 | 2003-09-18 | Merck & Co., Inc. | Method of treatment or prevention of obesity |
| JP3813152B2 (ja) | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
| EP1490043A4 (en) | 2002-03-26 | 2007-05-30 | Merck & Co Inc | SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS |
| ES2192494B1 (es) | 2002-03-27 | 2005-02-16 | Consejo Superior De Investigaciones Cientificas | Derivados de 1,2,4-triazol con propiedades cannabinoides. |
| US7271266B2 (en) | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| US20050154202A1 (en) | 2002-04-05 | 2005-07-14 | Hagmann William K. | Substituted aryl amides |
| FR2838438A1 (fr) | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
| FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
| AU2003223510B2 (en) | 2002-04-12 | 2008-05-08 | Merck Sharp & Dohme Corp. | Bicyclic amides |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| CA2493313C (en) | 2002-07-29 | 2010-03-09 | F. Hoffmann-La Roche Ag | Novel benzodioxoles |
| EP1558252B1 (en) | 2002-08-02 | 2007-10-10 | Merck & Co., Inc. | Substituted furo [2,3-b]pyridine derivatives |
| WO2004034968A2 (en) | 2002-08-20 | 2004-04-29 | The Regents Of The University Of California | Combination therapy for controlling appetites |
| HRP20050053A2 (en) | 2002-09-19 | 2005-04-30 | Solvay Pharmaceuticals B.V. | 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
| JP2006510597A (ja) | 2002-09-27 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 置換ピリミジン類 |
| BR0314872A (pt) | 2002-10-18 | 2005-08-02 | Pfizer Prod Inc | Ligandos do receptor canabinóide e usos dos mesmos |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| CA2510785C (en) | 2002-12-19 | 2013-04-09 | Merck & Co., Inc. | Substituted amides |
| GB0230087D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| BR0317931A (pt) | 2003-01-02 | 2005-11-29 | Hoffmann La Roche | Compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização dos compostos |
| ATE450505T1 (de) | 2003-01-02 | 2009-12-15 | Hoffmann La Roche | Cb 1 rezeptor inversagonisten |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| DE502004007000D1 (de) | 2003-02-13 | 2008-06-12 | Sanofi Aventis Deutschland | Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| EP1599480B1 (de) | 2003-02-13 | 2010-06-30 | Sanofi-Aventis Deutschland GmbH | Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US20040167188A1 (en) * | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
| US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
| EP1606019A1 (en) | 2003-03-07 | 2005-12-21 | The University Court of The University of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| AR045496A1 (es) * | 2003-08-29 | 2005-11-02 | Schering Corp | Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados |
| EP1711491A1 (en) | 2003-12-24 | 2006-10-18 | Prosidion Limited | Heterocyclic derivatives as gpcr receptor agonists |
| US7932394B2 (en) | 2004-11-02 | 2011-04-26 | Msd K.K. | Aryloxy-substituted benzimidazole derivatives |
| US20080312281A1 (en) | 2004-12-24 | 2008-12-18 | Matthew Colin Thor Fyfe | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes |
| EP1838706A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor agonists |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| JP5114395B2 (ja) | 2005-06-30 | 2013-01-09 | プロシディオン・リミテッド | Ｇｐｃｒアゴニスト |
| WO2007003961A2 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| MX2007016545A (es) | 2005-06-30 | 2008-02-21 | Prosidion Ltd | Agonistas del receptor acoplado a la proteina g. |
| AU2006264649A1 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
| EP2013201B1 (en) * | 2006-04-06 | 2012-07-25 | Prosidion Limited | Heterocyclic gpcr agonists |
-
2008
- 2008-01-04 SI SI200830454T patent/SI2114933T1/sl unknown
- 2008-01-04 PT PT08702095T patent/PT2114933E/pt unknown
- 2008-01-04 WO PCT/GB2008/050010 patent/WO2008081204A1/en not_active Ceased
- 2008-01-04 RS RS20110523A patent/RS52065B/sr unknown
- 2008-01-04 CA CA002674348A patent/CA2674348A1/en not_active Abandoned
- 2008-01-04 AT AT08702095T patent/ATE523507T1/de active
- 2008-01-04 PL PL08702095T patent/PL2114933T3/pl unknown
- 2008-01-04 HR HR20110852T patent/HRP20110852T1/hr unknown
- 2008-01-04 EP EP08702095A patent/EP2114933B1/en active Active
- 2008-01-04 ES ES08702095T patent/ES2373181T3/es active Active
- 2008-01-04 EP EP11174256A patent/EP2377863A1/en not_active Withdrawn
- 2008-01-04 JP JP2009544447A patent/JP2010514828A/ja active Pending
- 2008-01-04 DK DK08702095.4T patent/DK2114933T3/da active
- 2008-01-04 EA EA200900877A patent/EA015129B1/ru not_active IP Right Cessation
- 2008-01-04 US US12/522,015 patent/US20100048632A1/en not_active Abandoned
- 2008-01-04 BR BRPI0806498-9A2A patent/BRPI0806498A2/pt not_active IP Right Cessation
-
2011
- 2011-11-25 CY CY20111101161T patent/CY1112483T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514828A5 (Direct) | ||
| HRP20110852T1 (hr) | PIPERIDINSKI AGONISTI GPCR-a | |
| JP2022096662A5 (Direct) | ||
| JP2007523181A5 (Direct) | ||
| ES2376015T3 (es) | Agonistas de gpcr de tipo piperidina. | |
| JP2011500658A5 (Direct) | ||
| JP2013519680A5 (Direct) | ||
| JP2011500659A5 (Direct) | ||
| WO2015008230A1 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| US8822510B2 (en) | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | |
| JP2010501010A5 (Direct) | ||
| JP2010519243A5 (Direct) | ||
| JP2009519965A5 (Direct) | ||
| JP2013523819A (ja) | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 | |
| RU2006127572A (ru) | Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата | |
| EA018703B1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| JP2013507366A5 (Direct) | ||
| JP2010513319A5 (Direct) | ||
| JP2008500337A5 (Direct) | ||
| TW201113277A (en) | New thiadiazole derivatives | |
| JP2008526724A5 (Direct) | ||
| PE20040936A1 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
| RU2009138219A (ru) | Новые бензамидные производные и способ их получения | |
| JP2007508360A5 (Direct) | ||
| JP2004502670A5 (Direct) |